As fertility issues rise globally, the traditional American Dream becomes less attainable for many. AMS is building global trust through science-backed supplements, aiming to redefine reproductive wellness and offer hope to those affected.

The American Society for Gravitational and Space Research is now accepting abstracts for its 2025 conference in Phoenix. From December 3-6, scientists and engineers from all career stages will gather to share research, build collaborations, and discuss emerging issues in space science.

A new report from Exactitude Consultancy predicts that the molecular targeted therapy market will surpass $246 billion by 2034, marking significant growth in the healthcare sector.

A pioneering fragrance company is on a mission to revive the scents of flowers that have vanished from our world, offering a sensory journey back in time.

Faricimab has demonstrated greater fluid reduction than high-dose aflibercept at 12 weeks, offering new hope for patients with diabetic macular edema and age-related macular degeneration. These findings could influence future treatment approaches for these common eye conditions.

NASA strategically divides its life science research into Space Biology and Astrobiology, fostering collaboration between life scientists and physical scientists. This approach aims to understand how biological systems acclimate, adapt, and evolve in space, advancing NASA’s life science objectives.

In a surprising move, the Trump administration has canceled a $766 million contract with Moderna Inc. aimed at developing vaccines against potential pandemic flu strains, including the deadly H5N1 bird flu.

NASA’s Mars Perseverance rover snapped a selfie as a Martian dust devil blew by, capturing a unique moment on the Red Planet. The rover’s photo offers a rare glimpse into the Martian environment.

Biomedical engineers at Georgia Tech have developed an experimental treatment that trains the immune system to recognize and eliminate hard-to-treat cancers. The approach showed success in lab tests without harming healthy tissues and prevented cancer from returning.

Cantor Fitzgerald has reaffirmed its ‘overweight’ rating on Capricor Therapeutics (NASDAQ: CAPR). The brokerage set a $30 price target and estimated FY2025 earnings at $1.71 per share.

A driverless truck’s delivery in Dallas isn’t just a technological milestone—it’s a signal of the profound changes stirring within Texas politics that could reshape the nation. Sometimes, the smallest events herald the biggest transformations.

With over 48 million Americans affected by hearing loss, Audien’s over-the-counter hearing aids are reshaping accessibility and affordability in a once prohibitive market. By eliminating traditional barriers like high costs and prescriptions, Audien offers discreet, advanced solutions that empower users to reconnect with the world around them.

A Russian research associate at Harvard University has been detained since February after being charged with smuggling frog embryos into the United States. Facing possible deportation, her lawyer disputes the allegations as “meritless.”

ADAMA Ltd. has announced U.S. registration for Temper More, a new herbicide offering a powerful defense against herbicide-resistant weeds in row crops.

Lenovo has introduced a new humanoid robot in China capable of performing Tai Chi, symbolizing a remarkable blend of technology and tradition. Dubbed a potential ‘silicon employee’, this innovation could signify a transformative step in robotics and the future workforce.

Ukrainian tech professionals worldwide are leveraging their expertise to bolster their nation’s defense, signaling a technological uprising amid conflict. As Ukraine faces unprecedented challenges, its well-established tech community steps up, potentially paving the way for Europe’s next Silicon Valley.

The CEO of Travere Therapeutics has recently sold $398,000 worth of company stock, according to a report by Investing Us. This significant insider transaction highlights executive activity within the company.

Cuprina Holdings, a biomedical company specializing in chronic wound management and cosmeceuticals, has announced the pricing of its initial public offering at $4.00 per share. The firm commitment offering includes 3,000,000 Class A Ordinary Shares, aiming to raise $12 million.

Vertex Pharmaceuticals is poised to announce its first-quarter earnings for 2025 after the market closes on Monday, May 5th. Analysts project robust financial results, anticipating earnings of $4.24 per share and revenue of $2.85 billion. The company has also set its fiscal year 2025 guidance at earnings per share.

Genmab announces plans to submit a supplemental Biologics License Application to the FDA for a combination therapy targeting relapsed or refractory follicular lymphoma, potentially offering new hope to patients.

Coloplast A/S has updated its financial guidance for the fiscal year 2024/25 and pre-announced key financial figures for the first half of the year. This significant move signals important developments for investors and stakeholders alike.